Cauda equina neuroendocrine tumors show biological features distinct from other paragangliomas and visceral neuroendocrine tumors
- PMID: 36348031
- DOI: 10.1007/s00428-022-03441-1
Cauda equina neuroendocrine tumors show biological features distinct from other paragangliomas and visceral neuroendocrine tumors
Abstract
Cauda equina neuroendocrine tumors (CENETs) are neoplasms of uncertain histogenesis with overlapping features between those of paragangliomas (PGs) and visceral neuroendocrine tumors (NETs). We have explored their biological relationship to both subsets of neuroendocrine neoplasms. The clinical and radiological features of a cohort of 23 CENETs were analyzed. A total of 21 cases were included in tissue microarrays, along with a control group of 38 PGs and 83 NETs. An extensive panel of antibodies was used to assess epithelial phenotype (cytokeratins, E-cadherin, EpCAM, Claudin-4, EMA, CD138), neuronal and neuroendocrine features (synaptophysin, chromogranin A, INSM1, neurofilaments, NeuN, internexin-α, calretinin), chromaffin differentiation (GATA3, Phox2b, tyrosine hydroxylase), and possible histogenesis (Sox2, T-brachyury, Oct3/4, Sox10). The cohort included 5 women (22%) and 18 men (78%). The average age at the time of surgery was 48.3 years (range from 21 to 80 years). The average diameter of the tumors was 39.27 mm, and invasion of surrounding structures was observed in 6/21 (29%) tumors. Follow-up was available in 16 patients (median 46.5 months). One tumor recurred after 19 months. No metastatic behavior and no endocrine activity were observed. Compared to control groups, CENETs lacked expression of epithelial adhesion molecules (EpCAM, CD138, E-cadherin, Claudin-4), and at the same time, they lacked features of chromaffin differentiation (GATA3, Phox2b, tyrosine hydroxylase). We observed no loss of SDHB. Cytokeratin expression was present in all CENETs. All the CENETs showed variable cytoplasmic expression of T-brachyury and limited nuclear expression of Sox2. These findings support the unique nature of the neoplasm with respect to NETs and PGs.
Keywords: Cauda equina; Immunohistochemistry; Neuroendocrine tumors; Paragangliomas; Sox2.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin.Am J Surg Pathol. 2023 Apr 1;47(4):469-475. doi: 10.1097/PAS.0000000000002009. Epub 2022 Dec 22. Am J Surg Pathol. 2023. PMID: 36543154
-
SDH-B, INSM1, and GATA3 expression in cauda equina neuroendocrine tumors: report on 21 cases from a North indian tertiary care center.Hum Pathol. 2023 Jul;137:18-24. doi: 10.1016/j.humpath.2023.04.011. Epub 2023 Apr 24. Hum Pathol. 2023. PMID: 37100233
-
Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity.Acta Neuropathol. 2020 Dec;140(6):893-906. doi: 10.1007/s00401-020-02218-7. Epub 2020 Sep 14. Acta Neuropathol. 2020. PMID: 32926213 Free PMC article.
-
Cauda equina neuroendocrine tumor: a report of three cases and review of the literature with focus on differential diagnosis and postoperative management.Neurosurg Rev. 2024 Apr 17;47(1):166. doi: 10.1007/s10143-024-02405-0. Neurosurg Rev. 2024. PMID: 38632184 Review.
-
Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.Endocr Pathol. 2022 Mar;33(1):90-114. doi: 10.1007/s12022-022-09704-6. Epub 2022 Mar 13. Endocr Pathol. 2022. PMID: 35285002 Review.
Cited by
-
Intradural paragangliomas in the cauda equina region: a case report and literature review.Front Oncol. 2025 Aug 7;15:1642760. doi: 10.3389/fonc.2025.1642760. eCollection 2025. Front Oncol. 2025. PMID: 40852478 Free PMC article.
References
-
- Moran CA, Rush W, Mena H (1997) Primary spinal paragangliomas: a clinicopathological and immunohistochemical study of 30 cases. Histopathology 31:167–173. https://doi.org/10.1046/j.1365-2559.1997.2300841.x - DOI - PubMed
-
- Ramani B, Gupta R, Wu J, Barreto J, Bollen AW, Tihan T, Mummaneni PV, Ames C, Clark A, Oberheim Bush NA, Butowski N, Phillips D, King BE, Bator SM, Treynor EC, Zherebitskiy V, Quinn PS, Walker JB, Pekmezci M et al (2020) The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma. Acta Neuropathol 140:907–917. https://doi.org/10.1007/s00401-020-02221-y - DOI - PubMed - PMC
-
- Schweizer L, Thierfelder F, Thomas C, Soschinski P, Suwala A, Stichel D, Wefers AK, Wessels L, Misch M, Kim HY, Jodicke R, Teichmann D, Kaul D, Kahn J, Bockmayr M, Hasselblatt M, Younsi A, Unterberg A, Knie B et al (2020) Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. Acta Neuropathol 140:893–906. https://doi.org/10.1007/s00401-020-02218-7 - DOI - PubMed - PMC
-
- Miliaras GC, Kyritsis AP, Polyzoidis KS (2003) Cauda equina paraganglioma: a review. J Neuro-Oncol 65:177–190. https://doi.org/10.1023/b:neon.0000003753.27452.20 - DOI
-
- Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, Rathmell WK, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS, Cancer Genome Atlas Research N, Pacak K, Nathanson KL, Wilkerson MD (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181-193. https://doi.org/10.1016/j.ccell.2017.01.001
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous